Prescription medicine
Brimonidine and carbachol Brand names: Yuvezzi
Brimonidine and carbachol (Yuvezzi) is a prescription medicine with an FDA approval on record since 2026. No generic is listed in FDA's NDC Directory.
- No generic listed
Check it at the source: the brimonidine and carbachol FDA label on DailyMed (effective May 27, 2026, Visus Therapeutics, Inc.); the NDA 220142 record on Drugs@FDA; every brimonidine and carbachol label on DailyMed.
Highlights of the record
FDA label of May 27, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026
Used for
From the label: indications and usageYUVEZZI™ is indicated for the treatment of presbyopia in adults.
Forms and strengths
- 27.5 mg/ml / 1 mg/ml
Solution/ drops.
On the market
- Earliest approval on file
- January 28, 2026 Yuvezzi, Visus; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 1 of which 0 under generic applications, 1 under brand applications, repackagers included
- Last listed patent
- November 10, 2042 Yuvezzi solution/drops; not a generic launch date
Supply and safety
- Pharmacy cost (NADAC)
- Not in the survey
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 38 through July 30, 2026
What is brimonidine and carbachol used for?
From the label: indications and usageYUVEZZI™ is indicated for the treatment of presbyopia in adults. YUVEZZI is a combination of carbachol, a cholinergic agonist, and brimonidine, an alpha-adrenergic receptor agonist, indicated for the treatment of presbyopia in adults.
FDA pharmacologic class: Cholinergic Receptor Agonist and alpha-Adrenergic Agonist.
Source: FDA drug label (YUVEZZI), Visus Therapeutics, Inc., effective May 27, 2026 (SPL set 68198098-0f33-458f-83b8-eb2a5ec69012), via openFDA; the full label on DailyMed
Is there a generic for brimonidine and carbachol (Yuvezzi)?
No generic brimonidine and carbachol is approved (Drugs@FDA, October 8, 2026).
The Orange Book lists 2 patents for Yuvezzi solution/drops, the last expiring on November 10, 2042. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.
- 2026 earliest approval on file
- 2042 last listed patent
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What does the brimonidine and carbachol label say about other medicines?
The brimonidine and carbachol label names 1 other medicine in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Clonidine | drug interactions | DRUG INTERACTIONS Antihypertensives/cardiac glycosides may lower blood pressure. ( 7.1 ) Use with CNS depressants may result in an additive or potentiating effect. ( 7.2 ) Tricyclic antidepressants may potentially blunt the hypotensive effect of systemic clonidine. … |
Source: FDA drug label (YUVEZZI), Visus Therapeutics, Inc., effective May 27, 2026 (SPL set 68198098-0f33-458f-83b8-eb2a5ec69012), via openFDA; the full label on DailyMed
What do FAERS reports show for brimonidine and carbachol?
The FDA Adverse Event Reporting System holds 38 reports that list brimonidine and carbachol among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 0 are coded as a death and 0 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Other cholinergic receptor agonists
- the pharmacologic class, with prices and generics
- Brimonidine and carbachol side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other